Celyad Oncology GAAP EPS of -€1.81
- Celyad Oncology press release (NASDAQ:CYAD): FY GAAP EPS of -€1.81.
- As of December 31, 2022, the Company had cash and cash equivalents of €12.4 million ($13.3 million).
- The Company projects that its existing cash and cash equivalents should be sufficient to fund operating expenses and capital expenditure requirements into the fourth quarter of 2023.